Biotech Values

[DewDiligence]

Your Copaxone post is spot-on and crystallizes what I was driving at in my reply to Peter in #msg-48120081:

Notwithstanding the copious disclosures in the Copaxone patents, one presumably needs MNTA’s informatics tools—or some equally powerful toolset—to convert this knowledge into a full-fledged, commercial process.

Together with the disclosures in the Copaxone process patents, MNTA’s proprietary informatics tools allow MNTA to specify the batch-to-batch tolerances of branded Copaxone and thereby ensure that every batch of the generic product falls within these tolerances. Exactly as you stated.